Technology Snapshot



toxSYN™ Payloads

Bispecific Antibodies

Bispecific Antibodies

Immunotherapy is a rapidly expanding mainstay in the cancer treatment regimen where bispecific antibodies currently represent a $10Bn market and have experienced a CAGR of 118% through 2019 (Kuick Research – Feb 2020). 

Most prominently, blinatumomab has shown dramatic efficacy in treatment of adult acute lymphoblastic leukemia (ALL). However, the antibody requires cumbersome administration and faces toxicity issues such as cytokine release syndrome (CRS).

New technologies are expected to overcome the limitations of the first generation T cell engagers, however all require recombinant DNA technology to combine the two requisite antibody binding domains together into the final therapeutic drug.  Synaffix has taken a much simpler and faster non-genetic approach to combining the two binding domains covalently, following independent expression.

Just as in our approach to ADCs, GlycoConnect™ bispecifics are prepared from a full-sized, unmodified IgG where a second binding domain is stably attached to the native glycan with full control over stoichiometry, resulting in a pre-defined molecular format of 2:2 or 2:1.

Together with off-the-shelf protein payloads (i.e. anti-CD3, IL-15, others), this modular approach enables the rapid generation of a bispecific cell engager or immune bispecific checkpoint inhibitors (within a week) from any IgG.  

Just as with GlycoConnect™ ADCs, if your company has an IgG against a Target of interest, Synaffix has a fully complimentary tool kit to rapidly co-discover a novel, proprietary bispecific for your pipeline.